Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks
Cells · 23.10.2025 · 14 (21) · 1660
DOI: 10.3390/cells14211660 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 23.10.2025. Verfasst von Georgy E Leonov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Federal Research Center of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia. Hauptthemen laut MEDLINE: Stem Cell Transplantation, Cell- and Tissue-Based Therapy, Stem Cells. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education and Science.
Abstract (Originalsprache)
Regenerative medicine is a rapidly evolving field of contemporary biomedical research that offers new therapeutic strategies for conditions previously considered untreatable. Cell therapy shows particular potential in this domain. However, rigorous biosafety measures are required in its development and clinical application. This review proposes a practice-oriented biosafety framework for cell therapy, translating key risks into operational principles: toxicity, oncogenicity/tumorigenicity/teratogenicity, immunogenicity, biodistribution; and cell product quality. For each principle, preclinical approaches and regulatory expectations are summarized. Criteria for immunological safety are addressed, including activation of innate immunity (complement, T- and NK-cell responses) and the need for HLA typing. Biodistribution assessment involves the use of quantitative PCR and imaging techniques (PET, MRI) to monitor cell fate over time. The risks of oncogenicity, tumorigenicity, and teratogenicity can be analyzed using a combination of in vitro methods and in vivo models in immunocompromised animals. Product quality assessment includes sterility, identity, potency, viability, and genetic stability, with alignment of procedures to regulatory requirements and an emphasis on quality-by-design principles to ensure safe and reproducible clinical use. Integrating toxicity and safety pharmacology data supports a balanced risk–benefit assessment and clinical trial planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Federal Research Center of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia.
- Research Institute of Molecular and Cellular Medicine of the Medical Institute Peoples' Friendship, University of Russia, 117198 Moscow, Russia.
- Research Centre for Medical Genetics, 115478 Moscow, Russia.
ORCID-Profile: Georgy E Leonov, Oleg V Makhnach, Marina V Samburova, Diana I Salikhova
Förderung
- Ministry of Education and Science
Zitieren
APA
Leonov, G. E., Grinchevskaya, L. R., Makhnach, O. V., Samburova, M. V., Goldshtein, D. V., & Salikhova, D. I. (2025). Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks. Cells, 14(21), 1660. https://doi.org/10.3390/cells14211660
Vancouver
Leonov GE, Grinchevskaya LR, Makhnach OV, Samburova MV, Goldshtein DV, Salikhova DI. Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks. Cells. 2025;14(21):1660. doi:10.3390/cells14211660
BibTeX
@article{Leonov2025,
author = {Leonov, Georgy E and Grinchevskaya, Lydia R and Makhnach, Oleg V and Samburova, Marina V and Goldshtein, Dmitry V and Salikhova, Diana I},
title = {Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks},
journal = {Cells},
year = {2025},
volume = {14},
number = {21},
pages = {1660},
doi = {10.3390/cells14211660}
}
EUVIMED